Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Next Previous
Search
Trial Profile

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favezelimab (Primary) ; Lenvatinib (Primary) ; Olaparib (Primary) ; Pembrolizumab (Primary) ; Antineoplastics; Antineoplastics
  • Indications Haematological malignancies; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-587; MK-3475-587/KEYNOTE-587
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 26 Feb 2025 Study arms increased from 9 to 15. New drugs added to the study arms. Drugs olaparib and favezelimab added newly.
    • 15 Sep 2024 According to a Merck AG Media Release, results of this study being presented at ESMO include an analysis of the efficacy and safety outcomes for 211 former KEYNOTE-006 participants who transitioned to KEYNOTE-587 (KEYTRUDA, n=159; ipilimumab, n=52) after 10 years of follow-up and an analysis of additional antitumor activity in patients who received a second course of KEYTRUDA.
    • 21 Dec 2023 The given protocol has been amended as above- 1) Planned number of patients has been changed from 2300 to 3500. 2) Number of treatment arms has been changed from 5 to 9.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top